An Immunotherapy Used to Treat Non-Muscle Invasive Bladder Cancer Bacillus Calmette-Guerin (BCG) is an immunotherapy derived ...

Adjuvant BCG therapy of superficial bladder cancer remains the most successful immunotherapy for human malignancies and surpasses the efficacy of intravesical chemotherapy. Importantly ...

BCG-refractory cases (the most severe type of BCG failure) and those with carcinoma in situ (CIS)—an aggressive surface-spreading form of bladder cancer had 24mRFS rates ~10% lower. However, for these ...

“Bladder cancer is a large area of medical need, particularly in patients where BCG has failed,” said Vijay Kasturi, MD, Senior Vice President, Scientific Affairs. “There have been few ...

There are few treatment options for patients who develop BCG-unresponsive bladder cancer, which raises the risk of the cancer spreading throughout the body. Around 40% of patients don’t respond ...

for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The analyst writes, “Anktiva has the potential to revolutionize cancer ...

Though they may seem like something from the future, these five cancer vaccines are available now. Here are details about who ...

J&J reported positive results from the phase 2 SunRISe-1 study of TAR-200 in non–muscle-invasive bladder cancer (NMIBC) unresponsive to first-line therapy with BCG, achieving a 77% overall ...

Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today ...

Available vaccines include the HPV vaccine for cervical, anal, head, and neck cancers, Hepatitis B vaccine for liver cancer, BCG for bladder cancer, and Sipuleucel-T for metastatic prostate cancer.

In this section, we will analyze the mechanisms attributed to BCG cancer immunotherapy for bladder cancer. Over 100 years ago, pathological studies unearthed an association between mycobacterial ...

ImmunityBio's Anktiva shows high complete response rates in trials, enhancing immunotherapy for BCG-unresponsive bladder cancer. EF Hutton has initiated coverage on ImmunityBio Inc. IBRX ...